Skip to main content
Erschienen in: InFo Neurologie + Psychiatrie 4/2018

18.04.2018 | Schizophrenie | zertifizierte fortbildung

Herausforderung in der klinischen Praxis der Psychiatrie und Psychotherapie

Medikamentöse Behandlungsresistenz bei der Schizophrenie

verfasst von: Dr. med. Mirjam Handrack, PD. Dr. med Alkomiet Hasan

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die pharmakologische und nicht pharmakologische Behandlung von Erkrankungen aus dem schizophrenen Formenkreis in Fällen der medikamentösen Behandlungsresistenz ist eine große Herausforderung in der klinischen Praxis der Psychiatrie und Psychotherapie. Abhängig von der Definition erfüllen bis zu 60 % der betroffenen Personen die Kriterien für eine medikamentöse Behandlungsresistenz. Der folgende Artikel gibt eine Übersicht über die Definition, die Diagnostik und das Management der medikamentösen Behandlungsresistenz bei der Schizophrenie.
Literatur
1.
Zurück zum Zitat Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS medicine. 2005; 2(5):e141CrossRef Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS medicine. 2005; 2(5):e141CrossRef
2.
Zurück zum Zitat DGPPN. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 - Behandlungsleitlinie Schizophrenie. Gaebel Wf, Falkai, P., Weinmann, S., Wobrock T., editor. Darmstadt: Steinkopff-Verlag; 2006 DGPPN. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 - Behandlungsleitlinie Schizophrenie. Gaebel Wf, Falkai, P., Weinmann, S., Wobrock T., editor. Darmstadt: Steinkopff-Verlag; 2006
3.
Zurück zum Zitat Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. The American Journal of Psychiatry. 1994; 151(10):1409–16CrossRef Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. The American Journal of Psychiatry. 1994; 151(10):1409–16CrossRef
4.
Zurück zum Zitat Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Current medical research and opinion 1997; 14(1):1–20CrossRef Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Current medical research and opinion 1997; 14(1):1–20CrossRef
5.
Zurück zum Zitat Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. 2017; 174(3):216–29CrossRef Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. 2017; 174(3):216–29CrossRef
6.
Zurück zum Zitat Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. The Journal of Clinical Psychiatry 2014; 75 Suppl 1:8–14CrossRef Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. The Journal of Clinical Psychiatry 2014; 75 Suppl 1:8–14CrossRef
7.
Zurück zum Zitat Leucht S. Behandlungsresistenz. In: Falkai P, editor. Praxishandbuch Schizophrenie. 1: Elsevier; 2016. p. 162-3CrossRef Leucht S. Behandlungsresistenz. In: Falkai P, editor. Praxishandbuch Schizophrenie. 1: Elsevier; 2016. p. 162-3CrossRef
8.
Zurück zum Zitat NICE TNIfHaCE. Psychosis and schizophrenia in adults: prevention and management. 2014 NICE TNIfHaCE. Psychosis and schizophrenia in adults: prevention and management. 2014
9.
Zurück zum Zitat Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia bulletin. 2010; 36(1):71–93CrossRef Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia bulletin. 2010; 36(1):71–93CrossRef
10.
Zurück zum Zitat Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2012; 13(5):318–78CrossRef Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2012; 13(5):318–78CrossRef
11.
Zurück zum Zitat Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of general psychiatry 1988; 45(9):789–96PubMed Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of general psychiatry 1988; 45(9):789–96PubMed
12.
Zurück zum Zitat Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry. 2016; 73(3):199–210CrossRef Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry. 2016; 73(3):199–210CrossRef
13.
Zurück zum Zitat Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. The British journal of psychiatry: the journal of mental science 2016; 209(5):385–92CrossRef Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. The British journal of psychiatry: the journal of mental science 2016; 209(5):385–92CrossRef
14.
Zurück zum Zitat McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry 2006; 163(4):600–10CrossRef McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry 2006; 163(4):600–10CrossRef
15.
Zurück zum Zitat Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Archives of General Psychiatry 2000; 57(10):987–94CrossRef Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Archives of General Psychiatry 2000; 57(10):987–94CrossRef
16.
Zurück zum Zitat Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia bulletin 2006; 32(4):715–23CrossRef Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia bulletin 2006; 32(4):715–23CrossRef
17.
Zurück zum Zitat Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. The American Journal of Psychiatry 2016; 173(2):166–73CrossRef Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. The American Journal of Psychiatry 2016; 173(2):166–73CrossRef
18.
Zurück zum Zitat Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia. JAMA Psychiatry. 2017; 74(7):686–93CrossRef Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtala J, Hoti F, Jedenius E, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia. JAMA Psychiatry. 2017; 74(7):686–93CrossRef
19.
Zurück zum Zitat Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. The British Journal of Psychiatry 2012; 201(6):481–5CrossRef Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. The British Journal of Psychiatry 2012; 201(6):481–5CrossRef
20.
Zurück zum Zitat Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14:102CrossRef Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14:102CrossRef
21.
Zurück zum Zitat Miyamoto S, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. Current Opinion in Psychiatry 2015; 28(3):243–8CrossRef Miyamoto S, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. Current Opinion in Psychiatry 2015; 28(3):243–8CrossRef
22.
Zurück zum Zitat Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology 2012; 32(5):678–83CrossRef Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. Journal of Clinical Psychopharmacology 2012; 32(5):678–83CrossRef
23.
Zurück zum Zitat Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry 2017; 74(7):675–84CrossRef Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry 2017; 74(7):675–84CrossRef
24.
Zurück zum Zitat Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World psychiatry: official journal of the World Psychiatric Association 2017; 16(1):77–89CrossRef Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World psychiatry: official journal of the World Psychiatric Association 2017; 16(1):77–89CrossRef
25.
Zurück zum Zitat Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta psychiatrica Scandinavica. 2012; 125(1):15–24CrossRef Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta psychiatrica Scandinavica. 2012; 125(1):15–24CrossRef
26.
Zurück zum Zitat Sommer IE, Begemann MJH, Temmerman A et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012; 38:1003–11CrossRef Sommer IE, Begemann MJH, Temmerman A et al. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2012; 38:1003–11CrossRef
27.
Zurück zum Zitat Müller MJ, Benkert O. Antipsychotika. In: Benkert O, Hippius H, editors. Kompendium der Psychiatrischen Pharmakotherapie,. 11. Berlin, Heidelberg: Springer Verlag 2017; p. 269–488CrossRef Müller MJ, Benkert O. Antipsychotika. In: Benkert O, Hippius H, editors. Kompendium der Psychiatrischen Pharmakotherapie,. 11. Berlin, Heidelberg: Springer Verlag 2017; p. 269–488CrossRef
28.
Zurück zum Zitat Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. The American Journal of Psychiatry 2016; 173(9):876–86CrossRef Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. The American Journal of Psychiatry 2016; 173(9):876–86CrossRef
29.
Zurück zum Zitat Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry 2008; 69(2):274–85CrossRef Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry 2008; 69(2):274–85CrossRef
30.
Zurück zum Zitat Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. The Cochrane database of systematic reviews. 2005(2):CD000076. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. The Cochrane database of systematic reviews. 2005(2):CD000076.
31.
Zurück zum Zitat Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. The American Journal of Psychiatry 2015; 172(1):52–8CrossRef Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. The American Journal of Psychiatry 2015; 172(1):52–8CrossRef
32.
Zurück zum Zitat Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia research 2016; 171(1-3):215–24CrossRef Lally J, Tully J, Robertson D, Stubbs B, Gaughran F, MacCabe JH. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia research 2016; 171(1-3):215–24CrossRef
33.
Zurück zum Zitat Slotema CW, Blom JD, van Lutterveld R, Hoek HW, Sommer IE. Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biological Psychiatry 2014; 76(2):101–10CrossRef Slotema CW, Blom JD, van Lutterveld R, Hoek HW, Sommer IE. Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biological Psychiatry 2014; 76(2):101–10CrossRef
34.
Zurück zum Zitat Osoegawa C, Gomes JS, Grigolon RB, Brietzke E, Gadelha A, Lacerda ALT, et al. Non-invasive brain stimulation for negative symptoms in schizophrenia: An updated systematic review and meta-analysis. Schizophrenia Research 2018; doi: 10.1016/j.schres.2018.01.010 Osoegawa C, Gomes JS, Grigolon RB, Brietzke E, Gadelha A, Lacerda ALT, et al. Non-invasive brain stimulation for negative symptoms in schizophrenia: An updated systematic review and meta-analysis. Schizophrenia Research 2018; doi: 10.1016/j.schres.2018.01.010
35.
Zurück zum Zitat Wobrock T, Guse B, Cordes J, Wolwer W, Winterer G, Gaebel W, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biological psychiatry 2015; 77(11):979–88CrossRef Wobrock T, Guse B, Cordes J, Wolwer W, Winterer G, Gaebel W, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biological psychiatry 2015; 77(11):979–88CrossRef
Metadaten
Titel
Herausforderung in der klinischen Praxis der Psychiatrie und Psychotherapie
Medikamentöse Behandlungsresistenz bei der Schizophrenie
verfasst von
Dr. med. Mirjam Handrack
PD. Dr. med Alkomiet Hasan
Publikationsdatum
18.04.2018
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 4/2018
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-018-2370-y

Weitere Artikel der Ausgabe 4/2018

InFo Neurologie + Psychiatrie 4/2018 Zur Ausgabe